donepezil has been researched along with Parkinson Disease, Secondary in 1 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with donepezil was sometimes associated with worse parkinsonism." | 6.69 | Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. ( MacKnight, C; Rockwood, K; Shea, C, 1998) |
| "Treatment with donepezil was sometimes associated with worse parkinsonism." | 2.69 | Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. ( MacKnight, C; Rockwood, K; Shea, C, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shea, C | 1 |
| MacKnight, C | 1 |
| Rockwood, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies[NCT00230997] | Phase 3 | 50 participants | Interventional | 2002-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for donepezil and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Dementia; Donepezil; Female; Geriatric Assessme | 1998 |